SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.23 USD
+0.04 (1.83%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $2.20 -0.03 (-1.35%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SABS 2.23 +0.04(1.83%)
Will SABS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SABS
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Other News for SABS
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates | SABS Stock News
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
SAB Biotherapeutics (SABS) Stock Rating Maintained as Price Target Adjusted | SABS Stock News